8-K: BeyondSpring Sells $35.4 Million Stake in SEED Therapeutics to Fund Plinabulin Trials

BeyondSpring Inc. has entered into agreements to sell a portion of its equity in SEED Therapeutics for $35.4 million, which will be used to advance clinical trials for its lead asset, Plinabulin.

Summary

• BeyondSpring Inc. has agreed to sell a portion of its Series A-1 Preferred Shares in SEED Therapeutics Inc. for approximately $35.4 million.
• The sale involves three separate agreements with Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED, and Mapfil Investment Limited.
• The shares will be sold in three installments, with the first closing no later than February 24, 2025, the second no later than December 15, 2025, and the third no later than December 15, 2026.
• After the transactions, BeyondSpring and its subsidiary are expected to own approximately 14.4% of SEED's outstanding shares.
• The funds from the sale will be used to advance BeyondSpring's late-stage clinical trials for Plinabulin, its lead anti-cancer asset.

Sentiment

Score: 8

Explanation: The document is positive due to the non-dilutive funding secured through the sale of SEED shares, which will be used to advance the promising Plinabulin program. The company also retains a stake in SEED, allowing it to benefit from future growth. The language used is optimistic and forward-looking.

Positives

• The sale provides BeyondSpring with $35.4 million in non-dilutive funding.
• The funding will be used to advance the clinical trials of Plinabulin, a promising anti-cancer agent.
• BeyondSpring retains a significant ownership stake in SEED Therapeutics, allowing it to benefit from SEED's future success.
• The transaction validates SEED's technology and market potential, as evidenced by the recent Series A-3 financing led by Eisai at a $100 million pre-money valuation.
• Plinabulin has shown promising results in clinical trials, including significant overall survival benefit in NSCLC patients.

Negatives

• BeyondSpring will reduce its ownership stake in SEED Therapeutics to approximately 14.4%.
• The sale is contingent on various closing conditions, which could potentially delay or prevent the transaction.

Risks

• There is a risk that the closing conditions for the share purchase agreements may not be met, potentially delaying or preventing the transactions.
• The company faces risks related to the clinical development of Plinabulin, including potential delays or negative results.
• Macroeconomic conditions, including geopolitical instability and changes in interest rates and inflation, could impact the company's business.
• The company's future success is dependent on the continued development and commercialization of its pipeline assets.

Future Outlook

The company intends to use the proceeds from the sale to advance its Plinabulin clinical trials and explore business development partnerships. They also aim to remain part of SEED Therapeutics' future success.

Management Comments

• Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, stated that the capital will strategically position the company to advance its Plinabulin studies to registrational trials.
• Dr. Huang also mentioned that retaining a substantial stake in SEED Therapeutics ensures that they remain part of its continued success in revolutionizing drug discovery.

Industry Context

This announcement reflects a trend in the biopharmaceutical industry where companies are divesting non-core assets to focus on their lead programs. The sale of SEED Therapeutics shares allows BeyondSpring to capitalize on the value of its investment while securing funding for its primary focus, Plinabulin. The continued interest in TPD technology, as demonstrated by SEED's collaborations and financing, highlights the importance of this area in drug discovery.

Comparison to Industry Standards

• The sale of a minority stake in a subsidiary to fund core pipeline development is a common strategy in the biotech industry.
• The valuation of SEED Therapeutics at $100 million pre-money in its recent Series A-3 financing is comparable to other early-stage biotech companies in the TPD space.
• The use of proceeds to advance late-stage clinical trials is a standard practice for companies seeking to bring new therapies to market.
• The focus on Plinabulin's potential in NSCLC aligns with the industry's ongoing efforts to address unmet needs in this area, with companies like AstraZeneca, Merck, and Bristol Myers Squibb also heavily invested in lung cancer therapies.
• The clinical trial results for Plinabulin, particularly the overall survival benefit in the DUBLIN-3 study, are competitive with other late-stage lung cancer therapies.

Stakeholder Impact

• Shareholders will benefit from the non-dilutive funding and the potential for Plinabulin's success.
• Employees will have increased job security due to the company's improved financial position.
• Patients will potentially benefit from the development of new cancer therapies.
• SEED Therapeutics will continue to operate independently with a reduced ownership stake from BeyondSpring.

Next Steps

• The company will proceed with the closing of the share purchase agreements.
• BeyondSpring will use the proceeds to advance the clinical trials of Plinabulin.
• The company will explore business development partnerships for Plinabulin.
• The company will continue to monitor and support SEED Therapeutics' development.

Key Dates

Keywords

BeyondSpring, SEED Therapeutics, Plinabulin, share sale, clinical trials, oncology, targeted protein degradation, TPD, non-small cell lung cancer, NSCLC, investment, biopharmaceutical